CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges

CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges

Blog Article

The use of chimeric antigen receptor (CAR) in natural navy blue maang tikka killer (NK) cells for cancer therapy is gaining momentum, marking a significant shift in cancer treatment.This review aims to explore the potential of CAR-NK cell therapy in cancer immunotherapy, providing a fresh perspective.It discusses the innovative approaches in CAR-NK cell design and engineering, particularly targeting refractory or recurrent cancers.

By comparing CAR-NK cells with traditional therapies, the review highlights their unique ability to tackle tumor heterogeneity and cabin still decanter immune system suppression.Additionally, it explains how novel cytokines and receptors can enhance CAR-NK cell efficacy, specificity, and functionality.This review underscores the advantages of CAR-NK cells, including reduced toxicity, lower cost, and broader accessibility compared to CAR-T cells, along with their potential in treating both blood cancers and solid tumors.